Sign In
Last checked at 
29 Dec 2025 08:30
Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ - Monday, December 29, 2025: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:
1. | Name of applicant:
| HUTCHMED (China) Limited
| ||
2. | Name of scheme:
| Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")
| ||
3. | Period of return:
| From June 29, 2025 to December 28, 2025
| ||
4. | Balance under scheme from previous return:
| 2015 HUTCHMED Share Option Scheme: 45,992,018 ordinary shares of US$0.1 each
| ||
5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
| 2015 HUTCHMED Share Option Scheme: Nil
| ||
6. | Number of securities issued/allotted under scheme during period:
| 2015 HUTCHMED Share Option Scheme: 216,150
| ||
7. | Balance under scheme not yet issued/allotted at end of the period:
| 2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each
| ||
8. | Number and class of securities originally listed and the date of admission:
| 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) | ||
9. | Total number of securities in issue at the end of the period:
| 872,327,620 ordinary shares of US$0.1 each | ||
Name of contact:
| Weiguo Su / Johnny Cheng | |||
Address of contact:
| Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
| |||
Telephone number of contact: | +852 2121 8200 | |||
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
Media Enquiries | |
FTI Consulting - | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
Brunswick - Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
Panmure Liberum | Nominated Advisor and Joint Broker |
Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
Cavendish | Joint Broker |
Geoff Nash / Nigel Birks | +44 20 7220 0500 |
Deutsche Numis | Joint Broker |
Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
Follow the stocks
